Text Size

Metabolic Disorders in Polycystic Ovarian Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2004 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00172523
First received: September 12, 2005
Last updated: NA
Last verified: October 2004
History: No changes posted
  Purpose

The purpose of this study is to elucidate the significance of adipocytokine in women with PCOS among adiposity, hyperandrogenism and insulin resistance.


Condition
Polycystic Ovary Syndrome

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Study Start Date: October 2004
Estimated Study Completion Date: August 2005
Detailed Description:

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age with a probable prevalence of 5% to 10%. PCOS is characterized by chronic anovulation, menstrual irregularities, evidence of hyperandrogenism (either clinical, manifested as hirsutism, acne, male pattern balding, or biochemical, manifested by elevated serum adrenal and/or ovarian androgen concentration). Fifty percent of all patients with PCOS are obese, and the presence of obesity affects the clinical manifestations of PCOS. The underlying pathogenic mechanisms appear to involve insulin resistance and hyperinsulinemia, the magnitude of which is greater in obese than in non-obese women with PCOS.

  Eligibility

Ages Eligible for Study:   17 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Oligomenorrhea ( less than 6 times spontaneous MC per year) or Amenorrhea. 2. Hyperandrogenism (either clinical or biochemistry. 3. PCO by ultrasound. 4.After menarche, before menopause.

Exclusion Criteria:

  • 1. hormone therapy in the past 6 months. 2. Pregnancy in the past 6 months 3.Acute illness found in the past 3 months. 4.Systemic disease including autoimmune disease, malignancy, hepatic, renal or CVS disease, and ever received chemotherapy or immunosuppressive agents.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00172523

Contacts
Contact: Mei-Jou Chen, M.D. 886-2-23123456 ext 3950 metro@ha.mc.ntu.edu.tw

Locations
Taiwan
Department of Obstetrics and Gynecology, National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Mei-Jou Chen, M.D.     886-2-23123456 ext 3950     metro@ha.mc.tnu.edu.tw    
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Director: Horng-Nerng Ho, M.D. NTUH
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00172523     History of Changes
Other Study ID Numbers: 9361701094
Study First Received: September 12, 2005
Last Updated: September 12, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
 Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 16, 2013